Skip to main content
Premium Trial:

Request an Annual Quote

Artemis Pharma to Use Benitec s ddRNAi Technology for Mouse and Rat Models

NEW YORK, Oct. 28 (GenomeWeb News) - Benitec said today that it has granted a worldwide non-exclusive license to Artemis Pharmaceuticals for use of its proprietary ddRNAi technology in transgenic mouse and rat model development.

 

Benitec said it will receive an up-front license fee and ongoing royalties, but did not disclose additional financial details.

 

Artemis will use the ddRNAi technology to add in vivo gene knock-down capabilities to its ArteMice rodent model platform.

 

Benitec said that Artemis - a subsidiary of Exelixis based in Cologne, Germany - is the first European licensee for its ddRNAi technology.

 

In August, Benitec licensed the technology to GenScript and Ambion under patent infringement settlements related to its ddRNAi patent estate. A third patent infringement case, with Nucleonics, is still pending, following Nucleonics' requests to both the US and Australian patent authorities to re-examine Benitec's patents. 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.